COMP <GO>
XENE vs LLY // 10Y YIELD & FRED MACRO BETA
Xenon Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: XENE 2
— LLY 12
▲ 10Y YIELD & FRED MACRO BETA LEADER: XENE
LAST: $37.41 (-0.35%) • MKT CAP: $3.64B
macro-sensitivity
1.10
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XENE VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XENE | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 32.36% | -67.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.70% | 2.30% | -10.00 | LLY | /fcf-yield <GO> |
| Operating Margin | -36.70% | 40.21% | -76.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | -34.00% | 31.90% | -65.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | 45.51% | -37.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | XENE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.3 | 77.9 | -33.60 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.10 | 0.51 | +0.59 | XENE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 26.3x | +2.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.64B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XENE REV | LLY REV | XENE GROSS % | LLY GROSS % | XENE FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.18B | — | 83.0% | -$279.9M | $16.81B |
| FY 2024 | $0 | $45.04B | — | 81.3% | -$184.5M | $8.82B |
| FY 2023 | $0 | $34.12B | — | 79.3% | -$151.1M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XENE // BETA 1.10
LLY // BETA 0.51